Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

ALGAE4IBD –FROM NATURE TO BEDSIDE- ALGAE BASED BIO COMPOUND FOR PREVENTION AND TREATMENT OF INFLAMMATION, PAIN AND IBD

Projektbeschreibung

Tiefer Tauchgang zu entzündungshemmenden Algen

Liegt die Lösung für die Behandlung chronischer Erkrankungen in unseren Ozeanen, Flüssen oder Seen? Das EU-finanzierte Projekt Algae4IBD wird diese Frage beantworten. Das Forschungsteam wird Verbindungen aus Mikro- und Makroalgen (Seetang) aus dem Meer und Süßwasser vom Labor-/Pilot- bis zum Marktmaßstab untersuchen und dabei umfassend erforschen, wie aquatische natürliche biologische Ressourcen in biologisch aktive Verbindungen für die Prävention und Behandlung entzündlicher Darmerkrankungen umgewandelt werden können. Bei der Entwicklung algenbasierter Verbindungen soll mithilfe bahnbrechender Anbau- und Extraktionstechnologien insbesondere sichergestellt werden, dass die Biodiversität der Algen erhalten bleibt. Algae4IBD schlägt innovative Lösungen für die nachhaltige Nutzung algenbasierter Produkte mit höherem Nährwert vor, die sich positiv auf Menschen mit entzündlichen Darmerkrankungen auswirken.

Ziel

Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural biological resources. With the emerging developments in natural product, notable success has been achieved in discovering natural products and their synthetic structural analogues with anti-inflammatory activity. However, global biodiversity remains a largely unexploited resource for natural bioactive molecules with an enormous potential for developing commercial products with public health benefits. Micro and macroalgae, found in marine and freshwater, have been identified as promising sources of bioactive compounds including small molecules and secondary metabolites with a wide range of bioactivities as an antioxidant, anti-inflammatory and cancer preventive. Consumption of algae could, therefore, provide defence against chronic inflammatory diseases such as IBD, that until date have no effective cure. This project offers nature to bedside approach, using an entire development along the value chain for a new biodiscovery therapeutic approach by developing and examining algae-based compounds for IBD patients while guaranteeing algae's biodiversity preservation. We propose innovative solutions for increasing the use of algae-based ingredients and to ensure the science-based improvement of nutritional quality and its effect on public health. The researchers, companies and hospitals involved in the different stages of the project will use the biodiversity of algae, both micro and macro, as a wide source for bioactive compounds using state-of-the-art cultivation and extraction technologies for obtaining sufficient amounts of the bio-active molecules together with novel processing protocols. It will result in novel algal-based, high-quality bioactive compounds at GMP grade and lower costs for dual purposes – IBD prevention and treatment in relevance to the food as well as the pharmaceutical industries.

Aufforderung zur Vorschlagseinreichung

H2020-FNR-2020

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-FNR-2020-2

Koordinator

MIGAL GALILEE RESEARCH INSTITUTE LTD
Netto-EU-Beitrag
€ 1 177 948,49
Adresse
SOUTH INDUSTRIAL ZONE
11016 KIRYAT SHEMONA
Israel

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 1 177 948,49

Beteiligte (23)